Condition
Pituitary Macroadenoma
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02396810Not ApplicableTerminatedPrimary
Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas
NCT04212793Phase 1Completed
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
NCT01444209Phase 2TerminatedPrimary
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
Showing all 3 trials